Staar Surgical Company (NASDAQ: STAA) has announced the appointment of Deborah Andrews as its Chief Financial Officer. Ms. Andrews has been serving as the interim CFO since March 2025 and previously held the position from 2007-2013 and 2017-2020. Under her leadership, the company is on track to achieve a targeted $225 million annual SG&A run rate ahead of schedule.
In addition to the CFO appointment, the company has formed a Capital Stewardship Committee of the Board of Directors. This committee, chaired by board member Lilian Y. Zhou, will guide the company's financial strategies, including the responsible allocation, management, and oversight of capital. Ms. Zhou brings extensive experience in institutional investing and investment banking to lead this committee.
As part of the restructuring efforts, the company has restructured its investor relations function, resulting in the departure of Brian Moore, Vice President of Investor Relations and Corporate Development, effective June 27, 2025.
Staar Surgical is dedicated to enhancing long-term shareholder returns and is focused on reducing costs while driving sustainable growth and improving its cost structure to increase shareholder value.
Since 1982, Staar Surgical has been the global leader in implantable phakic intraocular lenses, with its proprietary biocompatible collamer material. The company's Evo ICL™ product line has provided visual freedom through a quick, minimally invasive procedure, with over 3 million ICLs sold in more than 75 countries.
As the new CFO takes the helm and the Capital Stewardship Committee is established, Staar Surgical is positioning itself to navigate the financial landscape and drive long-term value for its shareholders. Today the company's shares have moved -1.77% to a price of $16.875. Check out the company's full 8-K submission here.
